Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis DOI Creative Commons
Yao Luo, Jizhen Zhang,

Hongxia Guo

et al.

BMJ Open, Journal Year: 2025, Volume and Issue: 15(4), P. e088363 - e088363

Published: April 1, 2025

Objectives To evaluate the associations between alpha-lipoic acid (ALA) intake and intermediate disease markers in overweight or obese adults. Design Systematic review meta-analysis. Data sources PubMed, EMBASE, Medline, APA PsycINFO, SocINDEX, CINAHL, SSRN, SocArXiv, PsyArXiv, medRxiv, Google Scholar (from inception to October 2024). Eligibility criteria This study included English-language randomised controlled trials (RCTs) on adults (body mass index ≥25 kg/m²) assess impact of ALA markers. Studies lacking outcome data, duplicates inaccessible full texts were excluded. extraction synthesis Paired reviewers independently extracted data. We used frequentist meta-analysis summarise evidence, employing DerSimonian Laird estimator account for heterogeneity across designs, settings measurement methods. Heterogeneity was assessed via I² statistic with CIs τ² values. The risk bias by two according Cochrane Handbook, covering domains such as randomisation, blinding data completeness. Publication using Begg’s test, while funnel plots Egger’s test applied outcomes 10 more studies. Results 11 RCTs from an initial screening 431 studies, encompassing a total 704 results revealed no significant detected supplementation changes markers, including triglyceride (TG) (standardised mean difference (SMD): −0.08, 95% CI: −0.24 0.09, p=0.36, I²=0.00%, τ²=0.00), cholesterol (TC) (SMD: 0.08, −0.55 0.71, p=0.80, I²=87.50%, τ²=0.52), high-density lipoprotein (HDL-C) −0.05, −0.22 0.11, p=0.52, low-density (LDL-C) −0.13, −0.40 0.15, p=0.37, homeostasis model assessment insulin resistance (HOMA-IR) −0.23, −0.60 p=0.23, I²=26.20%, τ²=0.05) fasting blood glucose (FBS) 0.13, −0.16 0.41, p=0.39, I²=29.40%, τ²=0.04). According Grading Recommendations Assessment, Development Evaluation approach, eight studies rated having low (grade A), three moderate B). indicated evidence publication bias. Conclusions No TG, TC, HDL-C, LDL-C, HOMA-IR FBS levels, Further research is needed explore potential ALA, especially high-risk populations metabolic disorders, longer intervention durations, higher dosages optimised formulations. PROSPERO registration number CRD42023450239.

Language: Английский

Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis DOI Creative Commons
Yao Luo, Jizhen Zhang,

Hongxia Guo

et al.

BMJ Open, Journal Year: 2025, Volume and Issue: 15(4), P. e088363 - e088363

Published: April 1, 2025

Objectives To evaluate the associations between alpha-lipoic acid (ALA) intake and intermediate disease markers in overweight or obese adults. Design Systematic review meta-analysis. Data sources PubMed, EMBASE, Medline, APA PsycINFO, SocINDEX, CINAHL, SSRN, SocArXiv, PsyArXiv, medRxiv, Google Scholar (from inception to October 2024). Eligibility criteria This study included English-language randomised controlled trials (RCTs) on adults (body mass index ≥25 kg/m²) assess impact of ALA markers. Studies lacking outcome data, duplicates inaccessible full texts were excluded. extraction synthesis Paired reviewers independently extracted data. We used frequentist meta-analysis summarise evidence, employing DerSimonian Laird estimator account for heterogeneity across designs, settings measurement methods. Heterogeneity was assessed via I² statistic with CIs τ² values. The risk bias by two according Cochrane Handbook, covering domains such as randomisation, blinding data completeness. Publication using Begg’s test, while funnel plots Egger’s test applied outcomes 10 more studies. Results 11 RCTs from an initial screening 431 studies, encompassing a total 704 results revealed no significant detected supplementation changes markers, including triglyceride (TG) (standardised mean difference (SMD): −0.08, 95% CI: −0.24 0.09, p=0.36, I²=0.00%, τ²=0.00), cholesterol (TC) (SMD: 0.08, −0.55 0.71, p=0.80, I²=87.50%, τ²=0.52), high-density lipoprotein (HDL-C) −0.05, −0.22 0.11, p=0.52, low-density (LDL-C) −0.13, −0.40 0.15, p=0.37, homeostasis model assessment insulin resistance (HOMA-IR) −0.23, −0.60 p=0.23, I²=26.20%, τ²=0.05) fasting blood glucose (FBS) 0.13, −0.16 0.41, p=0.39, I²=29.40%, τ²=0.04). According Grading Recommendations Assessment, Development Evaluation approach, eight studies rated having low (grade A), three moderate B). indicated evidence publication bias. Conclusions No TG, TC, HDL-C, LDL-C, HOMA-IR FBS levels, Further research is needed explore potential ALA, especially high-risk populations metabolic disorders, longer intervention durations, higher dosages optimised formulations. PROSPERO registration number CRD42023450239.

Language: Английский

Citations

0